Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Quantum Genomics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 18, 2021

            Details:

            Phase III Pivotal REFRESH Study is part of firibastat’s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Faran Shimi Pharmaceutical Company

            Deal Size: Undisclosed Upfront Cash: $12.1 million

            Deal Type: Collaboration December 15, 2020

            Details:

            Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xediton Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: $11.3 million

            Deal Type: Licensing Agreement October 28, 2020

            Details:

            Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Qilu Pharmaceutical Co., Ltd.

            Deal Size: Undisclosed Upfront Cash: $50.0 million

            Deal Type: Licensing Agreement October 19, 2020

            Details:

            Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 13, 2020

            Details:

            First patient in the Company’s FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat(1) or resistant(2) hypertension. The study is being conducted jointly with its partner in Latin America, the Biolab Sanus Pharmaceutical laboratory.